Effect of elexacaftor-tezacaftor-ivacaftor on nasal potential difference and lung function in Phe508del rats

  • Front Pharmacol. 2024 Mar 13:15:1362325. doi: 10.3389/fphar.2024.1362325.
Nicole Reyne  1  2  3 ,  Patricia Cmielewski  1  2  3 ,  Alexandra McCarron  1  2  3 ,  Ronan Smith  1  2  3 ,  Elena Schneider-Futschik  4 ,  Nina Eikelis  5 ,  Piraveen Pirakalathanan  4 ,  David Parsons  1  2  3 ,  Martin Donnelley  1  2  3
Affiliations
  • 1. Robinson Research Institute, University of Adelaide, Adelaide, SA, Australia.
  • 2. Adelaide Medical School, University of Adelaide, Adelaide, SA, Australia.
  • 3. Respiratory and Sleep Medicine, Women's and Children's Hospital, Adelaide, SA, Australia.
  • 4. Department of Biochemistry and Pharmacology, School of Biomedical Sciences, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, VIC, Australia.
  • 5. 4DMedical, Carlton, VIC, Australia.
PMID: 38545546 DOI: 10.3389/fphar.2024.1362325
Abstract

Introduction: Phe508del is the most common cystic fibrosis transmembrane conductance regulator (CFTR) gene variant that results in the recessive genetic disorder cystic fibrosis (CF). The recent development of highly effective CFTR modulator therapies has led to significant health improvements in individuals with this mutation. While numerous animal models of CF exist, few have a CFTR mutation that is amenable to the triple combination therapy elexacaftor-tezacaftor-ivacaftor (ETI). Methods: To determine the responsiveness of Phe508del rats to ETI, a baseline nasal potential difference was measured. Subsequently, they received ETI daily for 14 days, after which post-treatment nasal potential difference, lung mechanics (via flexiVent) and lung ventilation (via X-ray Velocimetry) were assessed. Results: Chloride ion transport in nasal airways was restored in Phe508del rats treated with ETI, but neither lung mechanics nor ventilation were significantly altered. Discussion: These findings validate the usefulness of this rat model for future investigations of modulator therapy in CF.

Keywords
CFTR modulator; X-ray velocimetry; cystic fibrosis; lung function; nasal potential difference; rat model.
Products